Multiple Sclerosis and Cerebellar Ataxia DRG 060 Reimbursement

DRG 060 includes hospital admissions for multiple sclerosis and cerebellar ataxia without Complication or Comorbidity or Major Complication or Comorbidity, focusing on inpatient management of neurologic deficits. This Diagnosis-Related Group matters for inpatient reimbursement because it defines the base Medicare payment rate for routine care when higher-severity comorbid conditions are not present.

DRG 060 Overview

DRG 060 covers inpatient cases for patients with multiple sclerosis and cerebellar ataxia without Complication or Comorbidity or Major Complication or Comorbidity. It applies to hospital stays centered on management of neurologic dysfunction from demyelinating disease or cerebellar disorders when no higher-severity comorbid conditions are coded. This Diagnosis-Related Group groups clinically similar admissions to determine base Medicare payment for routine inpatient care. Accurate principal and secondary diagnosis coding influences assignment to this Diagnosis-Related Group and therefore the Medicare inpatient reimbursement level.

Acute relapse management and short-stay corticosteroid strategies: Trials in this area compare different high-dose corticosteroid regimens, routes of administration (oral versus IV), and adjunctive therapies during inpatient admissions for acute multiple sclerosis (MS) relapses or severe cerebellar ataxia exacerbations. The patient population includes adults admitted for neurologic worsening with objective deficits but without major comorbid complications (no CC/MCC), and studies measure time to neurological stabilization, length of stay, and early readmission. This research is relevant to providers and payers because optimizing inpatient acute management can reduce hospital days, prevent progression to higher-acuity care, and inform bundled payment or utilization protocols for DRG 060 admissions.
Comparative effectiveness of rehabilitation intensity and timing during hospitalization: These studies examine differing models and intensities of inpatient or early in-hospital multidisciplinary rehabilitation (physical therapy, occupational therapy, speech therapy, balance/gait training) for patients with MS-related motor impairment or cerebellar ataxia admitted for functional decline. The population focuses on patients without major complications who require short-term hospitalization to regain baseline function; outcomes include discharge disposition, functional scores at discharge, and 30- to 90-day post-discharge resource use. Findings are important to clinicians and payers because evidence on optimal rehabilitation approaches can guide length-of-stay decisions, post-acute service referrals, and cost-effective care pathways within the DRG.
Longitudinal outcomes and readmission prevention studies linking inpatient care to outpatient disease-modifying strategies: Research in this category follows patients admitted for MS or cerebellar ataxia without complications to evaluate how inpatient care transitions, education, and linkage to outpatient neurology and disease-modifying therapy management affect relapse rates, outpatient utilization, and avoidable readmissions. The cohort includes recently hospitalized patients who are ambulatory but vulnerable to early relapse or treatment gaps; endpoints include medication adherence, time to first outpatient neurology follow-up, and 90-day unplanned readmission. For providers and payers, these studies identify actionable transition-of-care interventions that may lower downstream costs and improve outcomes for the population classified under DRG 060.

Acute relapse management and short-stay corticosteroid strategies: Trials in this area compare different high-dose corticosteroid regimens, routes of administration (oral versus IV), and adjunctive therapies during inpatient admissions for acute multiple sclerosis (MS) relapses or severe cerebellar ataxia exacerbations. The patient population includes adults admitted for neurologic worsening with objective deficits but without major comorbid complications (no CC/MCC), and studies measure time to neurological stabilization, length of stay, and early readmission. This research is relevant to providers and payers because optimizing inpatient acute management can reduce hospital days, prevent progression to higher-acuity care, and inform bundled payment or utilization protocols for DRG 060 admissions.
Comparative effectiveness of rehabilitation intensity and timing during hospitalization: These studies examine differing models and intensities of inpatient or early in-hospital multidisciplinary rehabilitation (physical therapy, occupational therapy, speech therapy, balance/gait training) for patients with MS-related motor impairment or cerebellar ataxia admitted for functional decline. The population focuses on patients without major complications who require short-term hospitalization to regain baseline function; outcomes include discharge disposition, functional scores at discharge, and 30- to 90-day post-discharge resource use. Findings are important to clinicians and payers because evidence on optimal rehabilitation approaches can guide length-of-stay decisions, post-acute service referrals, and cost-effective care pathways within the DRG.
Longitudinal outcomes and readmission prevention studies linking inpatient care to outpatient disease-modifying strategies: Research in this category follows patients admitted for MS or cerebellar ataxia without complications to evaluate how inpatient care transitions, education, and linkage to outpatient neurology and disease-modifying therapy management affect relapse rates, outpatient utilization, and avoidable readmissions. The cohort includes recently hospitalized patients who are ambulatory but vulnerable to early relapse or treatment gaps; endpoints include medication adherence, time to first outpatient neurology follow-up, and 90-day unplanned readmission. For providers and payers, these studies identify actionable transition-of-care interventions that may lower downstream costs and improve outcomes for the population classified under DRG 060.

OpenPayer

Summary & Overview

Multiple Sclerosis and Cerebellar Ataxia without CC/MCC: Inpatient Reimbursement Overview

DRG 060 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes